These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2996208)

  • 41. More comments on COBTA's position on vaccine titers.
    Palmquist R
    J Am Vet Med Assoc; 2003 Mar; 222(6):714, 716. PubMed ID: 12675291
    [No Abstract]   [Full Text] [Related]  

  • 42. Killed vaccine response.
    Lawrie M
    Aust Vet J; 2005; 83(1-2):29. PubMed ID: 15971810
    [No Abstract]   [Full Text] [Related]  

  • 43. Preliminary development of a live attenuated canine parvovirus vaccine from an isolate of British origin.
    Churchill AE
    Vet Rec; 1987 Apr; 120(14):334-9. PubMed ID: 3035779
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of vaccination at 4 and 6 weeks in the control of canine parvovirus.
    De Cramer KG; Stylianides E; van Vuuren M
    Vet Microbiol; 2011 Apr; 149(1-2):126-32. PubMed ID: 21111542
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccination of dogs with Duramune DAPPi+LC protects against pathogenic canine parvovirus type 2c challenge.
    Wilson S; Stirling C; Borowski S; Thomas A; King V; Salt J
    Vet Rec; 2013 Jun; 172(25):662. PubMed ID: 23748583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early protection of puppies against canine parvovirus: a comparison of two vaccines.
    McCaw DL; Tate D; Dubovi EJ; Johnson JC
    J Am Anim Hosp Assoc; 1997; 33(3):244-50. PubMed ID: 9138235
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe parvovirus in a 12-year-old dog that had been repeatedly vaccinated.
    Decaro N; Cirone F; Desario C; Elia G; Lorusso E; Colaianni ML; Martella V; Buonavoglia C
    Vet Rec; 2009 May; 164(19):593-5. PubMed ID: 19429938
    [No Abstract]   [Full Text] [Related]  

  • 48. [Canine parvovirus: recent knowledge of the origin and development of a viral pathogen].
    Truyen U
    Tierarztl Prax; 1994 Dec; 22(6):579-84. PubMed ID: 7716757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Faecal shedding of canine parvovirus after modified-live vaccination in healthy adult dogs.
    Freisl M; Speck S; Truyen U; Reese S; Proksch AL; Hartmann K
    Vet J; 2017 Jan; 219():15-21. PubMed ID: 28093104
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Are vaccine strain, type or administration protocol risk factors for canine parvovirus vaccine failure?
    Altman KD; Kelman M; Ward MP
    Vet Microbiol; 2017 Oct; 210():8-16. PubMed ID: 29103701
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus.
    Spibey N; Greenwood NM; Sutton D; Chalmers WS; Tarpey I
    Vet Microbiol; 2008 Apr; 128(1-2):48-55. PubMed ID: 18006253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of antibodies to canine parvovirus and reaction to vaccination in client-owned, healthy dogs.
    Riedl M; Truyen U; Reese S; Hartmann K
    Vet Rec; 2015 Dec; 177(23):597. PubMed ID: 26514756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The effectiveness and safety of an immunization against parvovirus and rabies in anesthetized puppies].
    Mayr B; Hönig A; Gutbrod F; Wiedemann C
    Tierarztl Prax; 1990 Apr; 18(2):165-9. PubMed ID: 2161572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c.
    Wilson S; Illambas J; Siedek E; Stirling C; Thomas A; Plevová E; Sture G; Salt J
    Vaccine; 2014 Sep; 32(42):5420-4. PubMed ID: 25148778
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outbreak of canine parvovirus infection and its elimination in a closed beagle dog colony.
    Hirasawa T; Iwaki S; Watanabe K; Mikazuki K; Makino S; Hayashi Y
    Zentralbl Veterinarmed B; 1987 Oct; 34(8):598-606. PubMed ID: 2829474
    [No Abstract]   [Full Text] [Related]  

  • 56. Vaccination in the dog.
    Cornwell HJ; Thompson H
    In Pract; 1982 Sep; 4(5):151-2, 155-6, 158. PubMed ID: 6313526
    [No Abstract]   [Full Text] [Related]  

  • 57. Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CPV-2b and CPV-2c.
    Siedek EM; Schmidt H; Sture GH; Raue R
    Berl Munch Tierarztl Wochenschr; 2011; 124(1-2):58-64. PubMed ID: 21306055
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus.
    Gore TC; Lakshmanan N; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
    Vet Ther; 2005; 6(1):5-14. PubMed ID: 15906266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evolution of canine parvovirus--a need for new vaccines?
    Truyen U
    Vet Microbiol; 2006 Oct; 117(1):9-13. PubMed ID: 16765539
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccination at different anatomic sites induces different levels of the immune responses.
    Jin H; Xu Y; Shi F; Hu S
    Res Vet Sci; 2019 Feb; 122():50-55. PubMed ID: 30453180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.